The ubiquitous use of plastics, and the resulting disease burden from exposure to the endocrine-disrupting chemicals they contain, costs US society almost $250 billion a year.
A new study explores if the kidney failure risk equation can identify patients with type 2 diabetes who would show renal improvement with intensive glycemic management.
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.